CG Oncology, Inc.
Every calculator, already run for CGON
Open the full toolkit →You have the numbers on CGON. Get the argument.
A written report on which of these readings actually decide the outcome for CG Oncology, Inc., what has to stay true for the price to work, and the specific thing that would break it. The first one is free.
Key market data
Analyst consensus
14 analysts covering CGONAnalyst Price Target Disagreement for CG Oncology, Inc.
Wall Street's bull case implies +50% from the current price; the bear case implies +7%. A 43% spread signals high analyst disagreement — run your own DCF to anchor on fundamentals rather than street consensus.
Ownership & short interest
Insider Trading Activity for CGON
| Insider | Role | Type | Shares | Price | Value | Date | Filing |
|---|---|---|---|---|---|---|---|
About CG Oncology, Inc.
CG Oncology, Inc., a late-stage clinical biopharmaceutical company, develops and commercializes cretostimogene grenadenorepvec for patients with bladder cancer in the United States. The company's product candidate is cretostimogene, an investigational oncolytic immunotherapy, which is in phase 2 clinical trials of cretostimogene in patients with high-risk NMIBC after BCG failure; a phase 3 clinical trials to evaluate the safety and efficacy of cretostimogene as monotherapy in the treatment of patients who have received adequate BCG therapy with high-risk BCG-unresponsive, CIS-containing NMIBC and BCG-unresponsive Ta, or T1 papillary tumors; phase 3 BOND-003 Cohort C trials as a single agent;…
CGON — frequently asked
Is CGON a buy right now?
Wall Street's consensus rating on CG Oncology, Inc. is Strong Buy across 14 analysts, with a mean price target of $91.46 (+22% vs. the current $74.74). Ratings are a starting point — run the DCF and check the financial-health readings above before deciding.
What is the analyst price target disagreement for CG Oncology, Inc.?
Analysts covering CG Oncology, Inc. (CGON) range from a bear-case target of $80.00 to a bull-case high of $112.00, with a mean consensus target of $91.46 across 13 analysts. The spread of $32.00 (43% of the current price) indicates high disagreement on the outlook. Run the DCF calculator to build your own estimate independent of street consensus.
Compare CG Oncology, Inc. against related stocks
Explore additional stock overview pages and jump directly into full report generation for each symbol.
Sector peers
Most-followed names in the same sector.
Nearby tickers
Additional public equities from our tracked universe.
Market leaders
Large-cap symbols investors frequently compare.
Investor Guides For CG Oncology, Inc.
Start with the evergreen guides that matter most for Healthcare, then move back into the ticker page when you want to pressure-test the framework on a live name.
Generate your full CGON research report
DCF model, five-year financials, moat assessment, a BUY/HOLD/SELL rating, and the risks that matter — on CG Oncology, Inc., in minutes. 3 free reports included with every account — no credit card required.